Biblio Discovery — Demo Discovery Service

57 results for "Nancy U. Lin"

Showing 1–20 · 0.54 seconds · RSS

  1. Journal Article

    Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer

    Stefania Morganti; Heather A. Parsons; Nancy U. Lin et al.

    npj Breast Cancer, Vol. 9 No. 1 · 2023 · English · DOAJ Scopus

    Abstract A significant subset of patients with metastatic breast cancer develops brain metastasis. As efficacy of systemic therapies has improved and patients live longer with metastatic breast cancer, the incidence of breast cancer brain metastases has increased. Brain metastases pose a clinical…

  2. Journal Article

    Global challenges and policy solutions in breast cancer control

    Dario Trapani; Ophira Ginsburg; Temidayo A. Fadelu et al.

    Cancer Treatment Reviews · 2022 · English · OpenAlex Scopus

    Breast cancer is the leading cause of cancer morbidity, disability and mortality in women, worldwide. Overall, in 2020, it was the most diagnosed malignancy. Differences in breast cancer mortality have been historically evidenced, as a result of disparities in access to diagnosis, treatment and…

  3. Journal Article

    Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases

    Stacey Pan; Jayant Y. Gadrey; Sarah Sammons et al.

    Therapeutic Advances in Medical Oncology, Vol. 16 · 2024 · English · DOAJ Scopus

    Breast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local therapies (surgery, radiotherapy) and systemic treatments. Developing newer antibody–drug conjugates (ADCs)…

  4. Journal Article

    Integrative multiomics-histopathology analysis for breast cancer classification

    Yasha Ektefaie; William Yuan; Deborah A. Dillon et al.

    npj Breast Cancer, Vol. 7 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Histopathologic evaluation of biopsy slides is a critical step in diagnosing and subtyping breast cancers. However, the connections between histology and multi-omics status have never been systematically explored or interpreted. We developed weakly supervised deep learning models over…

  5. Journal Article

    Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

    Nancy U. Lin; Priya Kumthekar; Solmaz Sahebjam et al.

    npj Breast Cancer, Vol. 9 No. 1 · 2023 · English · DOAJ Scopus

    Abstract The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Primary analysis confirmed CNS objective…

  6. Journal Article

    The role of radiation therapy in leptomeningeal disease from breast cancer – a multicenter analysis

    Felix Ehret; Audrey Aitelli; Andrzej Niemierko et al.

    Clinical and Translational Radiation Oncology, Vol. 61 · 2026 · English · DOAJ Scopus

    Background: A subset of breast cancer patients will eventually develop leptomeningeal disease (LMD). There is a lack of large, in-depth analyses of the pattern of care and outcomes, with a particular focus on radiation therapy (RT). We report our experience in interdisciplinary LMD management…

  7. Journal Article

    Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan

    Laura Alder; Dario Trapani; Claire Bradbury et al.

    npj Breast Cancer, Vol. 9 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab…

  8. Journal Article

    The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study

    Kristen D. Brantley; Gregory J. Kirkner; Melissa E. Hughes et al.

    npj Breast Cancer, Vol. 11 No. 1 · 2025 · English · DOAJ Scopus

    Abstract The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or…

  9. Journal Article

    Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer

    Chiara Corti; Tianyu Li; Alyssa R. Martin et al.

    Breast, Vol. 87 · 2026 · English · DOAJ Scopus

    Background: Pathologic complete response (pCR) after neoadjuvant treatment (NAT) is prognostic for recurrence-free survival (RFS) and overall survival (OS) in breast cancer (BC). We assessed prognostic factors for RFS and OS in patients with pCR compared to residual disease (RD) in HER2+ and…

  10. Journal Article

    Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

    Thomas Grinda; Stefania Morganti; Liangge Hsu et al.

    npj Breast Cancer, Vol. 11 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Central nervous system (CNS) metastases are associated with poor prognosis in patients with metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) in 33 patients with HER2-negative MBC and CNS metastases, including active…

  11. Journal Article

    Adapting and Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care (Project ADAPT): Protocol for an Implementation Science–Based Study

    Ashley J Housten; Uzoma Charles Okere; Graham A Colditz et al.

    JMIR Research Protocols, Vol. 11 No. 7 · 2022 · English · DOAJ Scopus

    BackgroundMetastatic breast cancer (MBC) remains incurable despite significant treatment advances. Coordinating care for patients with MBC can be challenging given the various treatment options, available clinical trials, and frequent need for ancillary services. To optimize MBC care, we designed a…

  12. Journal Article

    Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

    Paolo Tarantino; Julieta Leone; Carlos T. Vallejo et al.

    npj Breast Cancer, Vol. 10 No. 1 · 2024 · English · DOAJ Scopus

    Abstract To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p

  13. Journal Article Full text

    STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

    Qiwei Wang; Johann S. Bergholz; Liya Ding et al.

    Nature Communications · 2022 · English · OpenAlex Scopus

    Abstract PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced ovarian tumors withBRCAmutations. However, the impact of this class of inhibitors in patients with advancedBRCA-mutant breast cancer is relatively modest. Using a syngeneic genetically-engineered mouse…

  14. Journal Article

    Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment

    Huijing Xue; Troy J. Kemp; Chenglei Li et al.

    Human Vaccines & Immunotherapeutics, Vol. 21 No. 1 · 2025 · English · DOAJ Scopus

    Individuals with cancer are at increased risk of severe COVID-19 and immunogenicity of SARS-CoV-2 vaccines may be compromised, especially in those receiving systemic anti-cancer treatment. Understanding how treatment affects vaccine-induced humoral responses is critical to optimize vaccination…

  15. Journal Article

    Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer

    Sonia Pernas; Jennifer L. Guerriero; Sergey Naumenko et al.

    Therapeutic Advances in Medical Oncology, Vol. 14 · 2022 · English · DOAJ Scopus

    Background: Inflammatory breast cancer (IBC) is a rare and understudied disease, with 40% of cases presenting with human epidermal growth factor receptor 2 (HER2)-positive subtype. The goals of this study were to (i) assess the pathologic complete response (pCR) rate of short-term neoadjuvant…

  16. Journal Article Full text

    Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases

    Timothy J. Kaufmann; Marion Smits; Jerrold L. Boxerman et al.

    Neuro-Oncology · 2020 · English · OpenAlex Scopus

    A recent meeting was held on March 22, 2019, among the FDA, clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocacy groups to discuss challenges and potential solutions for increasing development of therapeutics for central nervous system…

  17. Journal Article

    p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases

    Jing Ni; Sheheryar Kabraji; Shaozhen Xie et al.

    Nature Communications, Vol. 13 No. 1 · 2022 · English · DOAJ Scopus

    HER2+ breast cancer often develop brain metastases (BCBMs) that are difficult to treat. Here, the authors show that p16INK4A loss in BCBMs from HER2+ breast tumors results in resistance to the HER2 inhibitor Tucatinib, and that CDK4/6 inhibition can restore sensitivity to this drug.

  18. Journal Article

    Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study

    Adith Abraham; Carlos H. Barcenas; Richard J. Bleicher et al.

    Breast, Vol. 67 · 2023 · English · DOAJ Scopus

    Background: Most metastatic recurrences of triple negative breast cancer (TNBC) occur within five years of diagnosis, yet late relapses of TNBC (lrTNBC) do occur. Our objective was to develop a risk prediction model of lrTNBC using readily available clinicopathologic and sociodemographic features…